Not recruiting
Acute myeloid leukaemia+1
Not recruitingRegistered drugNo placebo
Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation
Registered drugNo placebo
- Disease:Acute myeloid leukaemiaMyelodysplastic syndrome with excess blasts
- Substances:GilteritinibMidostaurin
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Gilteritinib
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting



